Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14584179 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL4096506 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL29044161 | 1.00 | CYP3A4 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL19155610 | 0.83 | FUCA1 (0.33) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL712837 | 0.79 | CYP3A4 (0.39) | CYP3A4TSHRPOLBMAPK1GAA | |
| SCHEMBL28475631 | 0.78 | LGALS3 (0.33) | IDUA | |
| SCHEMBL2189191 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL2189182 | 0.77 | TSHR (0.45) | TSHR | |
| SCHEMBL28214269 | 0.77 | AHCY (0.34) | IDUA | |
| SCHEMBL14614369 | 0.76 | POLB (0.32) | CYP3A4TSHRPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3704107-B1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| CN-111278821-A | Spiro compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-06-12 | — | — | CN | disclosed |
| US-7977339-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2010519-B1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7795265-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| WO-2006015263-A2 | LONIDAMINE ANALOGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1476018-A4 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1476018-A1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6649172-B2 | 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants | CORIXA CORPORATION | 2003-11-18 | — | — | US | disclosed |
| US-20030190333-A1 | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins | CORIXA CORPORATION (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003069997-A1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1265840-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | CORIXA CORPORATION | 2001-12-20 | — | — | US | disclosed |
| WO-2001070663-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, GPBAR1 | CYP3A4 318/4885TSHR 792/4885POLB 4774/4885 |
| US-20030190333-A1 | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins | DDOST, TLR6, ENPP2 | CYP3A4 4187/4885TSHR 4542/4885POLB 2019/4885 |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | GALE, UGGT1, UGT1A3 | CYP3A4 76/4885TSHR 3312/4885POLB 2488/4885 |
| US-20100311649-A1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | CCKAR, CCKBR, GPR119 | CYP3A4 1362/4885TSHR 140/4885POLB 4855/4885 |
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | CYP3A4 3205/4885TSHR 4086/4885POLB 2253/4885 |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | CYP3A4 3345/4885TSHR 4073/4885POLB 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.